{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-337294","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2021-11-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.489125+00:00","generated_at":"2026-06-28T05:44:03.514601+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Aadi Bioscience receives FDA approval for FYARRO in advanced malignant PEComa","bullets":["FDA approved FYARRO (sirolimus protein-bound particles) for adult patients with advanced unresectable or metastatic malignant PEComa.","FYARRO is the first and only FDA-approved treatment for advanced malignant PEComa, an ultra-rare sarcoma.","In pivotal AMPECT trial, overall response rate was 39% (12/31); median duration of response not reached after median 36-month follow-up.","Launch planned for Q1 2022; investor conference call scheduled for today at 8:30 am ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-337294","json":"https://secwatch.observer/filing/0001193125-21-337294.json","markdown":"https://secwatch.observer/filing/0001193125-21-337294.md","text":"https://secwatch.observer/filing/0001193125-21-337294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521337294/0001193125-21-337294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521337294/d231595d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T05:44:03.514601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}